BACKGROUND: Sonic hedgehog (Shh) and Nrf2 play a critical role in chemotherapeutic resistance. These two genes have been found to be dysregulated in head and neck squamous cell carcinomas (HNSCC). The purpose of this study was to analyze the expression, function and clinical prognostic relationship of Shh and Nrf2 in HNSCC in the context of therapeutic resistance and cancer stem cells (CSCs). METHODS: We analyzed a cohort of patients with HNSCC to identify potential therapeutic biomarkers correlating with overall survival (OS) as well as disease-free survival (DFS) from our own data and validated these results using The Cancer Genome Atlas dataset. Expression of Shh and Nrf2 was knocked down by siRNA and cell growth, sphere growth and chemotherapeutic resistance were evaluated. RESULTS: Widespread abundant expression of Shh and Nrf2 proteins were associated with shorter OS and DFS. The combination of Shh and Nrf2 expression levels was found to be a significant predictor of patient DFS. The tumor stromal index was correlated with Shh expression and inversely associated with shorter OS and DFS. Inhibition of Shh by siRNA or cyclopamine resulted in the attenuation of resistant CSC self-renewal, invasion, clonogenic growth and re-sensitization to the chemotherapeutic agents. Concomitant upregulation of Shh and Nrf2 proved to be an independent predictor of poor OS and DFS in patients with HNSCC. CONCLUSIONS: These findings suggest that Shh and Nrf2 could serve as therapeutic targets as well as promising dual prognostic therapeutic biomarkers for HNSCC.
BACKGROUND: Sonic hedgehog (Shh) and Nrf2 play a critical role in chemotherapeutic resistance. These two genes have been found to be dysregulated in head and neck squamous cell carcinomas (HNSCC). The purpose of this study was to analyze the expression, function and clinical prognostic relationship of Shh and Nrf2 in HNSCC in the context of therapeutic resistance and cancer stem cells (CSCs). METHODS: We analyzed a cohort of patients with HNSCC to identify potential therapeutic biomarkers correlating with overall survival (OS) as well as disease-free survival (DFS) from our own data and validated these results using The Cancer Genome Atlas dataset. Expression of Shh and Nrf2 was knocked down by siRNA and cell growth, sphere growth and chemotherapeutic resistance were evaluated. RESULTS: Widespread abundant expression of Shh and Nrf2 proteins were associated with shorter OS and DFS. The combination of Shh and Nrf2 expression levels was found to be a significant predictor of patient DFS. The tumor stromal index was correlated with Shh expression and inversely associated with shorter OS and DFS. Inhibition of Shh by siRNA or cyclopamine resulted in the attenuation of resistant CSC self-renewal, invasion, clonogenic growth and re-sensitization to the chemotherapeutic agents. Concomitant upregulation of Shh and Nrf2 proved to be an independent predictor of poor OS and DFS in patients with HNSCC. CONCLUSIONS: These findings suggest that Shh and Nrf2 could serve as therapeutic targets as well as promising dual prognostic therapeutic biomarkers for HNSCC.
Authors: S S Islam; R B Mokhtari; A S Noman; M Uddin; M Z Rahman; M A Azadi; A Zlotta; T van der Kwast; H Yeger; W A Farhat Journal: Mol Carcinog Date: 2015-03-01 Impact factor: 4.784
Authors: Shao Hui Huang; Wei Xu; John Waldron; Lillian Siu; Xiaowei Shen; Li Tong; Jolie Ringash; Andrew Bayley; John Kim; Andrew Hope; John Cho; Meredith Giuliani; Aaron Hansen; Jonathan Irish; Ralph Gilbert; Patrick Gullane; Bayardo Perez-Ordonez; Ilan Weinreb; Fei-Fei Liu; Brian O'Sullivan Journal: J Clin Oncol Date: 2015-02-09 Impact factor: 44.544
Authors: Christine H Chung; James J Dignam; M Elizabeth Hammond; Alexander C Klimowicz; Stephanie K Petrillo; Anthony Magliocco; Richard Jordan; Andy Trotti; Sharon Spencer; Jay S Cooper; Quynh-Thu Le; K Kian Ang Journal: J Clin Oncol Date: 2011-02-28 Impact factor: 44.544
Authors: Gregory N Gan; Justin Eagles; Stephen B Keysar; Guoliang Wang; Magdalena J Glogowska; Cem Altunbas; Ryan T Anderson; Phuong N Le; J Jason Morton; Barbara Frederick; David Raben; Xiao-Jing Wang; Antonio Jimeno Journal: Cancer Res Date: 2014-10-08 Impact factor: 12.701
Authors: Chen Zhao; Alan Chen; Catriona H Jamieson; Mark Fereshteh; Annelie Abrahamsson; Jordan Blum; Hyog Young Kwon; Jynho Kim; John P Chute; David Rizzieri; Michael Munchhof; Todd VanArsdale; Philip A Beachy; Tannishtha Reya Journal: Nature Date: 2009-04-09 Impact factor: 49.962
Authors: Elisabeth Enzenhofer; Thomas Parzefall; Georg Haymerle; Sven Schneider; Lorenz Kadletz; Gregor Heiduschka; Johannes Pammer; Felicitas Oberndorfer; Fritz Wrba; Benjamin Loader; Matthäus Christoph Grasl; Christos Perisanidis; Boban M Erovic Journal: PLoS One Date: 2016-12-05 Impact factor: 3.240
Authors: Syed S Islam; Mohammed Uddin; Abu Shadat M Noman; Hosneara Akter; Nusrat J Dity; Mohammad Basiruzzman; Furkan Uddin; Jahanara Ahsan; Sunera Annoor; Ayodele A Alaiya; Monther Al-Alwan; Herman Yeger; Walid A Farhat Journal: EBioMedicine Date: 2019-05-10 Impact factor: 8.143
Authors: Syed S Islam; Khawlah Qassem; Shafiqul Islam; Rashed R Parag; Mohammed Z Rahman; Walid A Farhat; Herman Yeger; Abdelilah Aboussekhra; Bedri Karakas; Abu Shadat M Noman Journal: Cell Death Dis Date: 2022-08-09 Impact factor: 9.685